This content is available for reuse with permission. If you are interested in reusing this content, please email newsroom@davita.com.
As DaVita expands access to Expanded hemodialysis (HD), some patients who have recently started the treatment have shared positive personal experiences, including changes in how they feel day to day. These individual stories reflect patients’ perspectives and experiences and should not be interpreted as evidence of clinical outcomes for all patients. Real-World Patient Experiences The […]
DaVita will also continue hemodiafiltration (HDF) pilots to advance a comprehensive approach to middle molecule clearance. In the ongoing pursuit of improved outcomes in kidney care, few targets have been as stubborn as the middle molecule gap. When middle molecules — larger uremic toxins that are not effectively cleared during standard high-flux dialysis — accumulate, […]
By: Michael Moustakakis, MD, Group Medical Director for DaVita Extreme heat waves trigger standard public health advice everywhere: Drink plenty of water. For the general public, it’s a vital strategy to stay healthy and avoid heatstroke. But for the approximately 550,000 Americans living with end stage kidney disease (ESKD) and managing life on dialysis, this […]
With more than 90,000 people in the U.S. on the national transplant waitlist, the demand for life-saving organs far outpaces the supply. Living donation offers a strong pathway to addressing this public health challenge, and supporting a larger potential donor pool requires providing clarity on perceived barriers in the process. Angela Laino, a DaVita social […]
New data from the MOTheR trial1, one of the most rigorous head-to-head studies of advanced dialysis therapies to date, marks an important step forward in how the kidney care community approaches treatment for patients with end stage kidney disease. Presented at the European Renal Association (ERA) Congress in June 2026, the prospective randomized controlled trial […]